Compare TII & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TII | VYGR |
|---|---|---|
| Founded | 2012 | 2013 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 231.0M | 222.4M |
| IPO Year | N/A | 2015 |
| Metric | TII | VYGR |
|---|---|---|
| Price | $3.95 | $3.69 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $6.25 | ★ $17.00 |
| AVG Volume (30 Days) | ★ 1.5M | 745.6K |
| Earning Date | 03-20-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $75,461,000.00 | $31,316,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $71.77 |
| P/E Ratio | $30.14 | ★ N/A |
| Revenue Growth | ★ 54.36 | N/A |
| 52 Week Low | $0.26 | $2.65 |
| 52 Week High | $5.65 | $5.73 |
| Indicator | TII | VYGR |
|---|---|---|
| Relative Strength Index (RSI) | 49.18 | 38.11 |
| Support Level | $3.62 | $3.51 |
| Resistance Level | $4.66 | $4.09 |
| Average True Range (ATR) | 0.50 | 0.24 |
| MACD | -0.14 | -0.03 |
| Stochastic Oscillator | 8.87 | 11.89 |
Titan Mining Corp is a Canadian natural resources company. It is engaged in the acquisition, exploration, and development of mineral properties. The company owns an interest in the Empire State Mine in Northern New York State, United States. The Company operates one reportable segment, mineral production and exploration in the United States.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.